DK3290051T3 - Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer - Google Patents
Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer Download PDFInfo
- Publication number
- DK3290051T3 DK3290051T3 DK16786583.1T DK16786583T DK3290051T3 DK 3290051 T3 DK3290051 T3 DK 3290051T3 DK 16786583 T DK16786583 T DK 16786583T DK 3290051 T3 DK3290051 T3 DK 3290051T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- prevention
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015093640 | 2015-04-30 | ||
| PCT/JP2016/063420 WO2016175307A1 (ja) | 2015-04-30 | 2016-04-28 | 癌の治療及び／又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3290051T3 true DK3290051T3 (da) | 2020-01-06 |
Family
ID=57198482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16786583.1T DK3290051T3 (da) | 2015-04-30 | 2016-04-28 | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11129893B2 (da) |
| EP (1) | EP3290051B1 (da) |
| JP (1) | JP6862828B2 (da) |
| KR (1) | KR102729994B1 (da) |
| CN (1) | CN107530426A (da) |
| AU (1) | AU2016255255B2 (da) |
| BR (1) | BR112017022390A2 (da) |
| CA (1) | CA2983232A1 (da) |
| DK (1) | DK3290051T3 (da) |
| ES (1) | ES2762979T3 (da) |
| HU (1) | HUE047272T2 (da) |
| MX (1) | MX380750B (da) |
| PL (1) | PL3290051T3 (da) |
| PT (1) | PT3290051T (da) |
| RU (1) | RU2714205C2 (da) |
| WO (1) | WO2016175307A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112424357B (zh) * | 2018-06-26 | 2024-12-24 | 协和麒麟株式会社 | 与硫酸软骨素蛋白聚糖5结合的抗体 |
| AU2019295279A1 (en) | 2018-06-26 | 2021-01-21 | Kagoshima University | Antibody binding to cell adhesion molecule 3 |
| CN111073889B (zh) * | 2019-12-20 | 2023-07-28 | 中国人民解放军第四军医大学 | 人cspg5基因的用途及相关产品 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| JPH09194502A (ja) * | 1995-11-13 | 1997-07-29 | Seikagaku Kogyo Co Ltd | 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体 |
| JP4315257B2 (ja) | 1995-11-13 | 2009-08-19 | 生化学工業株式会社 | 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体 |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| TWI390034B (zh) | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
| CN101245386A (zh) * | 2008-03-26 | 2008-08-20 | 中南大学 | 用于多种肿瘤抑瘤基因检测的cDNA芯片 |
| JP5573156B2 (ja) | 2008-07-10 | 2014-08-20 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
| RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| EP2452950B1 (en) * | 2009-07-08 | 2017-11-15 | ACTGen, Inc. | Anti-podxl2 antibody having anti-cancer activity |
| JP2013013327A (ja) * | 2009-10-29 | 2013-01-24 | Actgen Inc | Ｍａｎｓｃ１蛋白質に結合し、抗癌活性を有する抗体 |
| KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
-
2016
- 2016-04-28 RU RU2017135005A patent/RU2714205C2/ru active
- 2016-04-28 US US15/567,496 patent/US11129893B2/en active Active
- 2016-04-28 KR KR1020177029174A patent/KR102729994B1/ko active Active
- 2016-04-28 WO PCT/JP2016/063420 patent/WO2016175307A1/ja active Application Filing
- 2016-04-28 PL PL16786583T patent/PL3290051T3/pl unknown
- 2016-04-28 AU AU2016255255A patent/AU2016255255B2/en active Active
- 2016-04-28 EP EP16786583.1A patent/EP3290051B1/en active Active
- 2016-04-28 BR BR112017022390-2A patent/BR112017022390A2/pt active Search and Examination
- 2016-04-28 MX MX2017013480A patent/MX380750B/es unknown
- 2016-04-28 PT PT167865831T patent/PT3290051T/pt unknown
- 2016-04-28 JP JP2016539232A patent/JP6862828B2/ja active Active
- 2016-04-28 ES ES16786583T patent/ES2762979T3/es active Active
- 2016-04-28 CA CA2983232A patent/CA2983232A1/en active Pending
- 2016-04-28 DK DK16786583.1T patent/DK3290051T3/da active
- 2016-04-28 HU HUE16786583A patent/HUE047272T2/hu unknown
- 2016-04-28 CN CN201680023169.6A patent/CN107530426A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3290051A1 (en) | 2018-03-07 |
| ES2762979T3 (es) | 2020-05-26 |
| WO2016175307A1 (ja) | 2016-11-03 |
| US20180085453A1 (en) | 2018-03-29 |
| BR112017022390A2 (pt) | 2018-10-23 |
| EP3290051A4 (en) | 2018-12-05 |
| MX380750B (es) | 2025-03-12 |
| PT3290051T (pt) | 2020-01-07 |
| EP3290051B1 (en) | 2019-10-23 |
| KR102729994B1 (ko) | 2024-11-14 |
| JPWO2016175307A1 (ja) | 2018-02-22 |
| US11129893B2 (en) | 2021-09-28 |
| PL3290051T3 (pl) | 2020-04-30 |
| AU2016255255B2 (en) | 2021-07-22 |
| KR20170141660A (ko) | 2017-12-26 |
| CA2983232A1 (en) | 2016-11-03 |
| RU2017135005A3 (da) | 2019-09-04 |
| RU2017135005A (ru) | 2019-04-08 |
| RU2714205C2 (ru) | 2020-02-13 |
| MX2017013480A (es) | 2017-12-07 |
| AU2016255255A1 (en) | 2017-11-02 |
| HUE047272T2 (hu) | 2020-04-28 |
| CN107530426A (zh) | 2018-01-02 |
| JP6862828B2 (ja) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3600281T3 (da) | Kombinationsbehandling til behandling eller forebyggelse af tumorer | |
| DK3616720T3 (da) | Farmaceutisk sammensætning til cancerbehandling | |
| DK2818481T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3153169T3 (da) | Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3270909T3 (da) | Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3191103T3 (da) | Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3174559T3 (da) | Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer | |
| DK3328368T3 (da) | Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3129378T3 (da) | Bromdomæne-hæmmende forbindelser og farmaceutisk sammensætning omfattende disse til forebyggelse eller behandling af en cancer | |
| DK3122743T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme | |
| DK3122367T3 (da) | Sammensætninger baseret på safran til forebyggelse og/eller behandling af degenerative øjenlidelser |